Ovarian Cancer Screening Congress

Proposed Programme

Day 1 - Tuesday, 29th November 2011

TIME	SESSIONS
09:00 - 09:15	Welcome Professor Ian Jacobs Vice-President and Dean of the Faculty of Medical and Human Sciences The University of Manchester, UK
09:15 - 09:30	Ovarian cancer – Overview of current diagnosis and management Mr Tim Mould Consultant Gynaecological Oncologist University College London Hospital, UK
	SESSION 1: DIFFERENTIAL DIAGNOSIS Chair: Professor Stuart Campbell
09:30 - 09:45	Novel biomarkers Professor Robert Bast Professor Gynaecological Oncology MD Anderson, USA
09:45 - 10:15	Refining ultrasound Professor Dirk Timmerman, Clinical Head of Gynaecology University Hospitals Gasthuisberg Campus, Belgium
10:15 - 10:25	Oral presentation: Diagnostic value of HE4, CA125 and the ROMA index in ovarian cancer patients from a tertiary center Dr Estrid Høgdall, Herlev Hospital, Denmark
10:25 - 10:35	Oral Presentation: Tumour-specific TP53 mutations in cell-free circulating DNA as a promising diagnostic marker for ovarian cancer Dr Nitzan Rosenfield, Cancer Research UK
10:35 - 11:00	Tea/Coffe Break & Exhibition/Poster Viewing
	SESSION 2: DEFINING RISK Chair: Professor Simon Gayther
11:00 - 11:30	Inherited risk Professor Simon Gayther Professor of Preventive Medicine University of Southern California, USA
11:30 - 12:00	Acquired Risk - reproductive and lifestyle factors Dr Susanne Krüger Kjær Head of Department of Virus, Hormones and Cancer Institute of Cancer Epidemiology Danish Cancer Society University of Copenhagen
12:00 - 12:30	Status of Risk Stratification Dr Paul Pharoah Senior Clinical Research Fellow University of Cambridge Strangeways Research Laboratory, UK
12:30 - 12:40	Oral presentation: Newly discovered high intermediate penetrance ovarian cancer susceptibility genes: clinical testing of RAD51D and RAD51C may have significant utility Dr Clare Turnbull, The Institute of Cancer Research, UK
12:40 - 12:50	Oral presentation: Use of dairy products, lactose, and calcium and risk of ovarian cancer – results from a Danish case-control study Mrs Faber Mette Tuxen, Danish Cancer Society, Denmark
12:50 - 13:45	Lunch Break & Exhibiton/Poster Viewing
	SESSION 3: GENERAL POPULATION SCREENING - CURRENT STATUS AND INSIGHTS FROM THE TRIALS Chair: Professor Ian Jacobs
13:45 - 14:15	PLCO Trial (USA) Dr Christine Berg Chief, Early Detection Research Group Division of Cancer Prevention, NIH, USA
14:15 - 14:45	UKCTOCS (UK) Prof Usha Menon Professor of Gynaecological Cancer University College London, UK
14:45 - 15:00	MD Anderson Ovarian Cancer Screening Trial (USA) Professor Robert Bast Professor Gynaecological Oncology MD Anderson, USA
15:00 - 15:30	Kentucky Utrasound Screening Study Dr Edward Pavlik Director, UK Ovarian Cancer Screening Research Program University of Kentucky Medical Center, USA
15:30 - 15:40	Oral Presentation: Population based testing for high-penetrance dominant gene mutations: inital results from the pilot phase of GCaPPS Dr Ranjit Manchanda, University College London, UK
15:40 - 15:50	Oral Presentation: Evidence for population-based BRCA1 and BRCA2 screening for ovarian cancer prevention Professor Ephrat Levy-Lahad, Shaare Zedek Medical Center, Israel
15:50 - 16:00	Oral Presentation: Surveillance of women at high risk of ovarian cancer: the Modena Study Group experience Dr Elisabetta De Matteis, Università degli studi di Modena e Reggio Emilia, Italy
16:00 - 16:30	Tea/Coffe Break & Exhibition/Poster Viewing
	SESSION 4: HIGH RISK POPULATION SCREENING - UPDATE FROM CURRENT TRIALS Chair: Professor Uzi Beller
16:30 - 17:00	ROCA and GOG0199 Screening Studies Dr Steve Skates Associate Professor of Medicine (Biostatistics) Harvard Medical School, USA
17:00 - 17:30	UK study - UKFOCCS Dr Adam Rosenthal Senior Lecturer Gynaecological Oncology QMUL Medical School, Barts and the London NHS Trust, UK
17:30	Sum-up of day 1

Day 2 - Wednesday, 30th November 2011

TIME	SESSIONS
	SESSION 5: NATURAL HISTORY OF OVARIAN CANCER Chair: Professor Martin Widschwendter
09:00 - 09:30	Serous ovarian cancer – defining targets for early detection site of origin Dr Pat Brown Stanford University School of Medicine, USA
09:30 - 10:00	Lead time of screening Prof Ian Jacobs Vice-President and Dean of the Faculty of Medical and Human Sciences The University of Manchester, UK
10:00 - 10:30	Insights from BRCA mutation carriers Prof Christopher P. Crum Professor, Department of Pathology, Harvard Medical School Director, Womens and Perinatal Pathology, Brigham And Women's Hospital, USA
10:30 - 10:40	Oral presentation: Telomeric instability in serous tubal intraepithelial carcinoma and tubo-ovarian dysplasia from prophylactic oophorectomies for genetic risk Dr Gautier Chene, Centre Jean Perrin, France
10:40 - 11:15	Tea/Coffe Break & Exhibition/Poster Viewing
	SESSION 6: BIOMARKERS AND SCREENING Chair: Dr Sudhir Srivastav
11:15 - 11:45	Development of screening algorithms using longitudinal biomarkers Dr Steve Skates Associate Professor of Medicine (Biostatistics) Harvard Medical School, USA
11:45 - 12:15	Biomarker discovery Dr Anna Lokshin Associate Professor of Medicine, Pathology and Ob/Gyn Reproductive Sciences Director of Luminex Core Facility University of Pittsburgh, USA
12:15 - 12:25	Oral Presentation: First promising results of blood transcriptomics in the detection of patients with ovarian cancer Professor Joachim Schultze, University of Bonn, Germany
12:25 - 12:35	Oral Presentation: Variation in epithelial-mesenchymal transition (EMT) genes and ovarian cancer risk Dr Catherine Phelan, Moffitt Cancer Center, USA
12:45 - 12:55	Oral Presentation: Potential role of HE4 in multimodal screening for epithelial ovarian cancer Dr Charles Drescher, Fred Hutchinson Cancer Research Center, USA
12:55 - 14:00	Lunch Break & Exhibiton/Poster Viewing
	SESSION 7: CONSENSUS WORKSHOP FOR ALL DELEGATES Quo Vadis? - Biomarker discovery for Ovarian Cancer Screening Chair: Professor Uzi Beller
14:00 - 14:10	Defining the Problem Professor Usha Menon Professor of Gynaecological Cancer University College London, UK
14:10 - 14:25	The Industry Perspective Dr Nicholas Hoyle Roche Diagnostics GmbH
14:25 - 14:35	The NCI Perspective - The Early Detection Research Network Dr Sudhir Srivastav Chief Cancer Biomarkers Research Group, USA
14:35 - 14:55	Tea/Coffe Break & Exhibition/Poster Viewing
14:55 - 16:30	Open Discussion
16:30 - 17:00	Summing Up Professor Uzi Beller Professor of Obstetrics & Gynaecology Shaare Zedek Medical Center, Jerusalem, Israel
17:00 - 17:10	Closing Remarks Professor Usha Menon
17:30	Close of conference